Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease

NCT06918808 is registered in ClinicalTrials.gov with Direct Biologics, LLC as lead sponsor.

NCT NCT06918808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06918808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease
Lead sponsor
Direct Biologics, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
May 19, 2025
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

perianal fistula due to crohn's disease